- Home
- GENC vs CRBU Comparison
GENC vs CRBU Comparison
Compare GENC & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENC | CRBU |
|---|---|---|
| Founded | N/A | 2011 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.4M | 203.9M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GENC | CRBU |
|---|---|---|
| Price | $15.14 | $1.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $16.00 | $10.00 |
| AVG Volume (30 Days) | 25.3K | ★ 1.0M |
| Earning Date | 05-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.08 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $48,943,000.00 | N/A |
| Revenue This Year | $125,306.93 | N/A |
| Revenue Next Year | $3.54 | $5.37 |
| P/E Ratio | $66.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.80 | $0.66 |
| 52 Week High | $17.40 | $3.53 |
Technical Indicators
Market Signals| Indicator | GENC | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | 51.53 |
| Support Level | $14.94 | $1.51 |
| Resistance Level | $16.00 | $1.64 |
| Average True Range (ATR) | 0.68 | 0.11 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 68.84 | 62.50 |
Price Performance
Historical ComparisonAbout GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.